Evonik stock holds on to its 2025 recovery as margins and cash flow matter

Evonik stock (ISIN DE000EVNK013) is being shaped by its 2025 operating rebound, with sales of EUR 15.2 billion, adjusted EBITDA of EUR 2.07 billion, and free cash flow of EUR 873 million. The company also reported that adjusted EBITDA rose 10% year on year in 2025, a comparison that gives the market a clean read on the earnings trend.

EUR 2.07 billion EBITDA

For investors, the most visible number is adjusted EBITDA of EUR 2.07 billion in 2025, up 10% from the prior year. Evonik also said 2025 sales reached EUR 15.2 billion, giving the margin profile more weight than top-line growth alone.

Free cash flow added another layer of support at EUR 873 million in 2025. That matters because cash generation, not just earnings, tends to set the tone for industrial names when the cycle is uneven.

Sales at EUR 15.2 billion

The 2025 sales figure of EUR 15.2 billion shows the group still operating at a large scale even as profitability takes priority. Adjusted EBITDA margin is not given here as a separate metric, but the combination of EUR 15.2 billion in sales and EUR 2.07 billion in adjusted EBITDA points to a business that is still converting a meaningful share of revenue into operating profit.

That 10% year-on-year EBITDA increase is the key comparison in the set. It gives the stock a clearer fundamental anchor than narrative alone and helps explain why margin sensitivity remains central to valuation.

Cash flow at EUR 873 million

Free cash flow of EUR 873 million in 2025 is the third number that matters most. In a capital-intensive chemicals business, that figure helps show whether earnings are turning into distributable or reinvestable cash.

The focus now is less on abstract sector positioning and more on whether the EUR 2.07 billion EBITDA base can be defended in 2026. The 2025 numbers establish the starting point.

Product and portfolio

Evonik's portfolio spans specialty chemicals used in areas such as animal nutrition, coatings, and care solutions. Those end markets matter because they determine how quickly sales and margins can respond when industrial demand improves or softens.

The 2025 reporting figures suggest the company is still judged on execution inside that portfolio rather than on a single headline product. For the stock, the next reference point will be whether cash generation and EBITDA can remain close to the 2025 levels.

Trading level to watch

The article is built around the latest evidenced operating numbers rather than a live quote. In that framework, Evonik stock remains tied to 2025 sales of EUR 15.2 billion, adjusted EBITDA of EUR 2.07 billion, and free cash flow of EUR 873 million.

Those figures frame the equity story as a margin and cash flow case, not a growth rerating case. The 10% rise in adjusted EBITDA is the most direct quantified comparison in the latest set.